Rhythm Pharmaceuticals

ISIN US76243J1051

 | 

WKN A2H5A0

Market cap (in EUR)
6,676 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 6,676 m
EPS, EUR -2.81
P/B ratio 52.7
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 120 m
Net income, EUR -241 m
Profit margin -200.27%

What ETF is Rhythm Pharmaceuticals in?

There are 2 ETFs which contain Rhythm Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Rhythm Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.64%
Equity
United States
Health Care
Biotech
43
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.09%
Equity
United States
Small Cap
180
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.